Granted Patent
B2
US 12,497,431 · App. 18/460,215 · Granted Dec 16, 2025
Modified peptide fragments of Cav-1 protein and the use thereof in the treatment of fibrosis
Assignee:
Rein Therapeutics, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Abstract
Provided herein are compositions comprising modified caveolin-1 (Cav-1) peptides. Further provided are methods of using the modified Cav-1 peptides for the treatment of lung infections or acute or chronic lung injury, particularly lung fibrosis.
Claims (27)
1 . A peptide comprising the amino acid sequence KASFTTFTVTKGS (SEQ ID NO: 4).
2 . The peptide of claim 1 , wherein the peptide comprises the amino acid sequence aaEGKASFTTFTVTKGSaa (SEQ ID NO: 6).
3 . The peptide of claim 1 , wherein the peptide is selected from the group consisting of KASFTTFTVTKGS-NH2 (SEQ ID NO: 5), aaEGKASFTTFTVTKGSaa-NH2 (SEQ ID NO: 7), and Ac-aaEGKASFTTFTVTKGSaa-NH2 (SEQ ID NO: 8).
4 . The peptide of claim 1 , wherein the peptide comprises: a) at least one amino acid added to the N-terminus of SEQ ID NO: 4; b) at least one amino acid added to the C-terminus of SEQ ID NO: 4; or c) at least one amino acid added to both the N-terminus and the C-terminus of SEQ ID NO: 4.
5 . The peptide of claim 1 , wherein the peptide comprises at least one non-standard amino acid.
6 . The peptide of claim 5 , wherein the non-standard amino acid is ornithine.
7 . The peptide of claim 1 , wherein the peptide comprises: a) D-amino acids; or b) both L- and D-amino acids.
8 . The peptide of claim 1 , wherein the peptide further comprises: a) an N-terminal modification; b) a C-terminal modification; or c) both N- and C-terminal modifications.
9 . The peptide of claim 8 , wherein the N-terminal modification is acylation; and/or the C-terminal modification is amidation.
10 . A pharmaceutical composition comprising the peptide of claim 1 and a pharmaceutically acceptable carrier.
11 . The pharmaceutical composition of claim 10 , wherein the pharmaceutical composition is formulated for oral, intravenous, intraarticular, parenteral, enteral, subcutaneous, intramuscular, topical, buccal, sublingual, intraocular, epidural, intracranial, or inhalational administration.
12 . The pharmaceutical composition of claim 10 , wherein the pharmaceutical composition is formulated for lung instillation.
13 . The pharmaceutical composition of claim 10 , wherein the pharmaceutical composition is formulated as an aqueous solution.
14 . A method of treating lung disease or disorder in a subject in need thereof, wherein the method comprises administering to the subject a pharmaceutical composition comprising a therapeutically effective amount of the peptide of claim 1 ; and wherein the lung disease is selected from the group consisting of pulmonary inflammation, chronic obstructive pulmonary disorder (COPD), acute lung injury, lung infection, chemical-induced lung injury, plastic bronchitis, asthma, acute respiratory distress syndrome (ARDS), inhalational smoke induced acute lung injury (ISALI), bronchiolitis, bronchiolitis obliterans, interstitial lung disease, pulmonary fibrosis and lung scarring.
15 . The method of claim 14 , wherein the lung disease or disorder is pulmonary fibrosis.
16 . The method of claim 15 , wherein the pulmonary fibrosis is idiopathic pulmonary fibrosis.
17 . The method of claim 14 , wherein the pharmaceutical composition is administered systemically or locally to the lung of the subject.
18 . The method of claim 14 , wherein the pharmaceutical composition is administered by inhalation to the subject.
19 . The method of claim 14 , wherein the pharmaceutical composition is administered by a nebulizer to the subject.
20 . The method of claim 14 , wherein the pharmaceutical composition is administered in a single dose to the subject.
21 . The method of claim 14 , wherein the pharmaceutical composition is administered in multiple doses to the subject.
22 . The method of claim 14 , wherein the pharmaceutical composition is administered in multiple doses; and the dose is administered once per day, once every two days, once per week, once every two weeks, or once per month.
23 . The method of claim 14 , wherein the pharmaceutical composition is administered at a dose between about 0.1 mg/kg to about 500 mg/kg.
24 . The method of claim 14 , wherein the pharmaceutical composition is administered at a dose between about 1 mg/kg to about 50 mg/kg.
25 . The method of claim 14 , wherein the pharmaceutical composition is administered at a dose between about 1 mg/kg to about 10 mg/kg.
26 . The method of claim 14 , wherein the method further comprises administering at least one additional therapeutic agent.
27 . The method of claim 26 , wherein the at least one additional therapeutic is a non-steroidal anti-inflammatory drug, steroid, immunosuppressive agent, biologic response modifier, bronchodilator, or anti-fibrotic agent.
Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Mar 3, 2025
From: LUNG THERAPEUTICS, LLC
To: REIN THERAPEUTICS, INC.
Reel/Frame 070384/0082 →
MERGER AND CHANGE OF NAME
Recorded Apr 9, 2024
From: LUNG THERAPEUTICS, INC.; AT MERGER SUB II, LLC
To: LUNG THERAPEUTICS, LLC
Reel/Frame 067041/0773 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Sep 8, 2023
From: CHRISTENSEN, DALE; KOLENG, JOHN J.
To: LUNG THERAPEUTICS, INC.
Reel/Frame 064839/0030 →
Continuity (4)
Continuation
17274721
Provisional Application
62728997
· Sep 10, 2018
References Cited (400)
US 4021387A
· Goetzl et al.
· 1977
[cited by applicant]
US 4554101A
· Hopp
· 1985
[cited by applicant]
US 4628045A
· Hahn
· 1986
[cited by applicant]
US 4719288A
· Fuhrer et al.
· 1988
[cited by applicant]
US 4816449A
· Hahn
· 1989
[cited by applicant]
US 5277175A
· Riggs et al.
· 1994
[cited by applicant]
US 5284133A
· Burns et al.
· 1994
[cited by applicant]
US 5299566A
· Davis et al.
· 1994
[cited by applicant]
US 5355872A
· Riggs et al.
· 1994
[cited by applicant]
US 5358934A
· Borovsky et al.
· 1994
[cited by applicant]
US 5464821A
· Stig et al.
· 1995
[cited by applicant]
US 5559209A
· Nishimoto
· 1996
[cited by applicant]
US 5660166A
· Lloyd et al.
· 1997
[cited by applicant]
US 5728680A
· Morozov et al.
· 1998
[cited by applicant]
US 5797389A
· Ryder
· 1998
[cited by applicant]
US 5823179A
· Grychowski et al.
· 1998
[cited by applicant]
US 5889155A
· Ashkenazi et al.
· 1999
[cited by applicant]
US 6016974A
· Mascitelli
· 2000
[cited by applicant]
US 6017735A
· O'Hare et al.
· 2000
[cited by applicant]
US 6041776A
· Briggs, III
· 2000
[cited by applicant]
US 6044841A
· Verdun et al.
· 2000
[cited by applicant]
US 6126939A
· Eisenbach-Schwartz et al.
· 2000
[cited by applicant]
US 6241159B1
· Ganan-Calvo et al.
· 2001
[cited by applicant]
US 6261569B1
· Comis et al.
· 2001
[cited by applicant]
US 6354516B1
· Patel et al.
· 2002
[cited by applicant]
US 6357671B1
· Cewers
· 2002
[cited by applicant]
US 6921020B2
· Ivri
· 2005
[cited by applicant]
US 6926208B2
· Ivri
· 2005
[cited by applicant]
US 6968840B2
· Smith et al.
· 2005
[cited by applicant]
US 6978941B2
· Litherland et al.
· 2005
[cited by applicant]
US 7040549B2
· Ivri et al.
· 2006
[cited by applicant]
US 7083112B2
· Ivri
· 2006
[cited by applicant]
US 7104463B2
· Litherland et al.
· 2006
[cited by applicant]
US 7332469B2
· Idell
· 2008
[cited by applicant]
US 7360536B2
· Patel et al.
· 2008
[cited by applicant]
US 7494976B2
· Sessa
· 2009
[cited by applicant]
US 8058227B2
· Hoffman et al.
· 2011
[cited by applicant]
US 8182838B2
· Morton et al.
· 2012
[cited by applicant]
US 8349798B2
· Sessa
· 2013
[cited by applicant]
US 8487072B2
· Beliveau et al.
· 2013
[cited by applicant]
US 8697840B2
· Shetty et al.
· 2014
[cited by applicant]
US 9630990B2
· Shetty et al.
· 2017
[cited by applicant]
US 9908915B2
· Sessa et al.
· 2018
[cited by applicant]
US 20020020409A1
· Kidwell et al.
· 2002
[cited by applicant]
US 20020020412A1
· Gilbert et al.
· 2002
[cited by applicant]
US 20020077283A1
· Sessa
· 2002
[cited by applicant]
US 20030113271A1
· Katyama et al.
· 2003
[cited by applicant]
US 20040175384A1
· Mohapatra et al.
· 2004
[cited by applicant]
US 20090068258A1
· Lisanti et al.
· 2009
[cited by applicant]
US 20090304666A1
· Harrison et al.
· 2009
[cited by applicant]
US 20110171193A1
· Zhao et al.
· 2011
[cited by applicant]
US 20110301142A1
· Hutchinson et al.
· 2011
[cited by applicant]
US 20120014917A1
· Kossen et al.
· 2012
[cited by applicant]
US 20150141340A1
· Sessa
· 2015
[cited by applicant]
US 20160279209A1
· Williams, III et al.
· 2016
[cited by applicant]
US 20180050084A1
· Williams, III et al.
· 2018
[cited by applicant]
US 20180086791A1
· Shetty et al.
· 2018
[cited by applicant]
US 20190062836A1
· Abbas et al.
· 2019
[cited by applicant]
US 20190224243A1
· Hoffman et al.
· 2019
[cited by applicant]
US 20200164028A1
· Williams, III et al.
· 2020
[cited by applicant]
US 20210330741A1
· Williams, III et al.
· 2021
[cited by applicant]
US 20220160814A1
· Wasnick et al.
· 2022
[cited by applicant]
US 20220370544A1
· Shetty
· 2022
[cited by applicant]
US 20230100467A1
· Shetty et al.
· 2023
[cited by applicant]
US 20230159608A1
· Windsor
· 2023
[cited by applicant]
US 20230190861A1
· Shetty
· 2023
[cited by applicant]
US 20230226149A1
· Mackenzie et al.
· 2023
[cited by applicant]
US 20240082342A1
· Shetty
· 2024
[cited by applicant]
US 20250041383A1
· Windsor
· 2025
[cited by applicant]
US 20250076312A1
· Mackenzie et al.
· 2025
[cited by applicant]
CN 101022830A
· 2007
[cited by applicant]
CN 102387784A
· 2012
[cited by applicant]
CN 102753148A
· 2012
[cited by applicant]
CN 107216394A
· 2017
[cited by applicant]
CN 107405379A
· 2017
[cited by applicant]
CN 111671886A
· 2020
[cited by applicant]
EP 0097994B1
· 1987
[cited by applicant]
EP 1076091A1
· 2001
[cited by applicant]
JP 2001509515A
· 2001
[cited by applicant]
JP 2005503321A
· 2005
[cited by applicant]
JP 2007161702A
· 2007
[cited by applicant]
JP 2010506860A
· 2010
[cited by applicant]
JP 2011506396A
· 2011
[cited by applicant]
JP 2012250981A
· 2012
[cited by applicant]
JP 2016522159A
· 2016
[cited by applicant]
JP 2016539188A
· 2016
[cited by applicant]
JP 2018507867A
· 2018
[cited by applicant]
JP 6975690B2
· 2021
[cited by applicant]
JP 7496826B2
· 2024
[cited by applicant]
KR 20050003416A
· 2005
[cited by applicant]
KR 20170122748A
· 2017
[cited by applicant]
KR 102268883B1
· 2021
[cited by applicant]
WO WO9902551A1
· 1999
[cited by applicant]
WO WO0111038A2
· 2001
[cited by applicant]
WO WO0220768A2
· 2002
[cited by applicant]
WO WO03016540A2
· 2003
[cited by applicant]
WO WO03094890A1
· 2003
[cited by applicant]
WO WO2008046228A1
· 2008
[cited by applicant]
WO WO2009074634A2
· 2009
[cited by applicant]
WO WO2009111625A2
· 2009
[cited by applicant]
WO WO2009152453A2
· 2009
[cited by applicant]
WO WO2010030813A2
· 2010
[cited by applicant]
WO WO2010048275A2
· 2010
[cited by applicant]
WO WO2011038283A1
· 2011
[cited by applicant]
WO WO2011098552A2
· 2011
[cited by applicant]
WO WO2013184482A1
· 2013
[cited by applicant]
WO WO2014145389A1
· 2014
[cited by applicant]
WO WO2015000371A1
· 2015
[cited by applicant]
WO WO2015066664A2
· 2015
[cited by applicant]
WO WO2015080943A1
· 2015
[cited by applicant]
WO WO2015080980A2
· 2015
[cited by applicant]
WO WO2016138413A1
· 2016
[cited by applicant]
WO WO2020055812A1
· 2020
[cited by applicant]
WO WO2020055824A1
· 2020
[cited by applicant]
WO WO2020106922A1
· 2020
[cited by applicant]
WO WO2020185826A1
· 2020
[cited by applicant]
WO WO2021216659A1
· 2021
[cited by applicant]
WO WO2021257816A2
· 2021
[cited by applicant]
WO WO2022182949A2
· 2022
[cited by applicant]
WO WO2022266410A1
· 2022
[cited by applicant]
WO WO2023070069A1
· 2023
[cited by applicant]
Gratton et al., “Selective inhibition of tumor microvascular permeability by cavtratin blocks tumor progression in mice”, Cancer Cell. Jul. 2003; 4(1): 31-39, and Correction in Cancer Cell. Jun. 10, 2024; 42(6): 1127, 1…
[cited by applicant]
Markarian, J., “Modernizing Pharma Manufacturing,” Pharmaceutical Technology Apr. 2018; 42(4): 20-25.
[cited by applicant]
Van Haren, et al., “Sterol carrier protein 2 (non-specific lipid transfer protein) is localized in membranous fractions of Leydig cells and Sertoli cells but not in germ cells”. Biochim Biophys Acta. Mar. 25, 1992; 1124…
[cited by applicant]
“Afrezza®”, Highlights of prescribing information, Manufactured by: MannKind Corporation, CT, USA, Initial US Approval: 2014, Revised: Feb. 2023, downloaded Dec. 5, 2024, https://afrezza.com/wp-content/uploads/2023/02/F…
[cited by applicant]
Aillon, K. et al., “Iodinated Nanoclusters as an Inhaled Computed Tomography Contrast Agent for Lung Visualization,” Molecular Pharmaceutics Jun. 24, 2010; 7(4): 1274-1282.
[cited by applicant]
Extended European Search Report for European Application No. 22760460.0 mailed Dec. 16, 2024, 8 pages.
[cited by applicant]
Extended European Search Report for European Application No. 24188856.9 mailed Oct. 31, 2024, 7 pages.
[cited by applicant]
Extended European Search Report for European Application No. 21826284.8 dated Jun. 11, 2024, 23 pages.
[cited by applicant]
“Exubera®”, NDA 21-868 US Package Insert, Distributed by: Pfizer Labs Division of Pfizer Inc., NY, USA, dated Jan. 27, 2007, downloaded Dec. 5, 2024, https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/021868lbl.p…
[cited by applicant]
International Preliminary Report on Patentability for International Application No. PCT/US2022/078482, mailed on May 2, 2024, 7 pages.
[cited by applicant]
Johnson and Mathay, “Acute Lung Injury: Epidemiology, Pathogenesis, and Treatment”. J Aerosol Med Pulm Dmg Deliv Aug. 2010; 23(4): 243-252.
[cited by applicant]
King, P.T., “Inflammation in chronic obstructive pulmonary disease and its role in cardiovascular disease and lung cancer,” Clin Transl Med. Dec. 2015; 4(1): 68, 13 pages. Epub Jul. 29, 2015.
[cited by applicant]
Llano, M. et al., “Blockade of human immunodeficiency virus type 1 expression by caveolin-1”. J Virol. Sep. 2002; 76(18): 9152-9164.
[cited by applicant]
Mikolka et al., “The Synthetic Surfactant CHF5633 Restores Lung Function and Lung Architecture in Severe Acute Respiratory Distress Syndrome in Adult Rabbits”. Lung. Jun. 2024; 202(3): 299-315. Epub Apr. 29, 2024.
[cited by applicant]
NCT04233814, “Safety, Tolerability and Pharmacokinetic Study of LTI-03 in Healthy Adult Subjects,” Lung Therapeutics, Inc., Last Update Posted Mar. 7, 2022, downloaded Nov. 1, 2024, https://clinicaltrials.gov/study/NCT0…
[cited by applicant]
NCT05954988, “Study to Evaluate LTI-03 in Newly Diagnosed Idiopathic Pulmonary Fibrosis (IPF) Patients,” Lung Therapeutics, Inc., Last Update Posted Aug. 30, 2023, downloaded Nov. 1, 2024, https://clinicaltrials.gov/stu…
[cited by applicant]
Ng et al., “Guidelines for surfactant replacement therapy in neonates”. Paediatric Child Health. Feb. 2021; 26(1): 35-41. Epub Feb. 1, 2021.
[cited by applicant]
O'Callaghan, C. et al., “The science of nebulised drug delivery”, Thorax, Apr. 1997; v52 Suppl 2(Suppl 2): vS31-44.
[cited by applicant]
Onnée, M. et al., “Instability of mature abca3 protein: toward a new classification of abca3 mutations?” American Journal of Respiratory Cell and Molecular Biology Nov. 2022; 67(5): 602-605.
[cited by applicant]
Rogliani, P. et al., “Optimizing drug delivery in COPD: The role of inhaler devices”, Respiratory Medicine, Mar. 2017; 124: 6-14. Epub Jan. 24, 2017.
[cited by applicant]
Rothe, T., et al., “Diagnosis and Management of Asthma—The Swiss Guidelines,” Respiration, 2018, vol. 95, pp. 364-380.
[cited by applicant]
Shetty, et al., “Caveolin-1-Related Intervention for Fibrotic Lung Diseases,” Cells. Feb. 9, 2023; 12(4): 554, 12 pages.
[cited by applicant]
Simmons Jr., G.E. et al., “Caveolin-1 suppresses human immunodeficiency virus-1 replication by inhibiting acetylation of NF-?B”. Virology. Oct. 10, 2012; 432(1): 110-119. Epub Jun. 28, 2012.
[cited by applicant]
Sweet et al., “A first-in-human clinical study of a new SP-B and SP-C enriched synthetic surfactant (CHF5633) in preterm babies with respiratory distress syndrome”. Arch Dis Child Fetal Neonatal Ed. Nov. 2017; 102(6): F…
[cited by applicant]
Welsh, C.H., et al., “An international ISHLT/ATS/ERS clinical practice guideline: summary for clinicians. Bronchiolitis obliterans syndrome complicating lung transplantation,” Ann Am Thorac Soc. Jan. 2015; 12(1): 118-11…
[cited by applicant]
Xing, Yifan et al., “Multifaceted Functions of Host Cell Caveolae/Caveolin-1 in Virus Infections”. Viruses. Apr. 26, 2020; 12(5): 487, 24 pages.
[cited by applicant]
Li, et al., “L-Leucine as an excipient against moisture on in vitro aerosolization performances of highly hygroscopic spray-dried powders”. Eur J Pharm Biopharm. May 2016; 102: 132-141. Epub Mar. 9, 2016.
[cited by applicant]
Loh et al., “Overview of milling techniques for improving the solubility of poorly water-soluble drugs”, Asian Journal of Pharmaceutical Science (2015); 10(4): 255-274.
[cited by applicant]
Sou, T., et al., “Designing a multi-component spray-dried formulation platform for pulmonary delivery of biopharmaceuticals: The use of polyol, disaccharide, polysaccharide and synthetic polymer to modify solid-state pr…
[cited by applicant]
Abdollahi, et al., “Inhibition of platelet-derived growth factor signaling attenuates pulmonary fibrosis”. J Exp Med. (Mar. 21, 2005); 201(6): 925-935.
[cited by applicant]
Agu et al., “The lung as a route for systemic delivery of therapeutic proteins and peptides,” Respir Res. 2001;2(4):198-209.
[cited by applicant]
Altman et al., “Predictors of survival in systemic sclerosis (scleroderma)”, Arthritis Rheum., 34:403-413, 1991.
[cited by applicant]
Anderson, “The caveolae membrane system”, Annu Rev Biochem, 67:199-225, 1998.
[cited by applicant]
Anonymous: “Caveolin-1 scaffolding domain peptide—ALX-153-064—Enzo Life Sciences”, Aug. 28, 2018 (Aug. 28, 2018), pp. 1-2, Retrieved from the Internet: URL: http://web.archive.org/web/20180828064451/https://www.enzolife…
[cited by applicant]
Ansel et al., Pharmaceutical Dosage Forms and Drug Delivery Systems (6th ED 1995) at pp. 196 and 1456-1457.
[cited by applicant]
Arbuzova et al., “Membrane Binding of Peptides Containing Both Basic and Aromatic Residues—Experimental Studies with Peptides Corresponding to the Scaffolding Region of Caveolin and the Effector Region of Marcks”, Bioch…
[cited by applicant]
Basire, et al., “High urokinase expression contributes to the angiogenic properties of endothelial cells derived from circulating progenitors”. Thromb Haemost Apr. 2006; 95(4): 678-688.
[cited by applicant]
Bellini et al., “The role of the fibrocytes, a bone marrow-derived mesenchymal progenitor, in reactive and reparative fibrosis”, Lab Invest, 2007, 13 pages.
[cited by applicant]
Beon et al., “Myofibroblast induction and microvascular alteration in scleroderma lung fibrosis”, Clin Exp Rheumatol, 22: 733-742, 2004.
[cited by applicant]
Bernatchez et al., “Dissecting the molecular control of endothelial NO synthase by caveolin-1 using cell-permeable peptides”, Proc Natl Acad Sci USA, 102:761-766, 2005.
[cited by applicant]
Bhandary et al., “Regulation of alveolar epithelial cell apoptosis and pulmonary fibrosis by coordinate expression of components of the fibrinolytic system”, Am J Physiol Lung Cell Mal Physiol., 302: L463-L473, 2012.
[cited by applicant]
Bhandary, et al., “Regulation of lung injury and fibrosis by p53-mediated changes in urokinase and plasminogen activator inhibitor-1”. Am J Pathol. Jul. 2013; 183(1): 131-143. Epub May 8, 2013.
[cited by applicant]
Bogatkevich et al., “Contractile Activity and Smooth Muscle alpha-actin organization in thrombin-induced human lung myofibroblasts”, J Physiol Lung Cell Mol Physiol, 85:L334-L343, 2003.
[cited by applicant]
Bogatkevich et al., “Thrombin differentiates normal lung fibroblasts to a myofibroblast phenotype via the proteolytically activated receptor-1 and a protein kinase C-dependent pathway”, J Biol Chem., 276:45184-45192, 20…
[cited by applicant]
Bonelli et al., “Solid phase synthesis of retro-inverso peptide analogues,” Int. J. Peptide Protein Res. 24(6), Apr. 26, 1984, pp. 553-556.
[cited by applicant]
Bordo et al., “Suggestions for “Safe” Residue Substitutions in Site-directed Mutagenesis,” Journal of Molecular Biology, vol. 217, Issue 4, Feb. 20, 1991, pp. 721-729.
[cited by applicant]
Boscher and Nabi, “Caveolin-1: role in cell signaling”. Adv Exp Med Biol. 2012; 729: 29-50.
[cited by applicant]
Bowie, J. U. et al., “Deciphering the message in protein sequences: Tolerance to amino acid substitutions,” Science, (Mar. 16, 1990), 247(4948):1306-1310.
[cited by applicant]
Britain's national health service web page on mesothelioma, [publication date unknown], page last reviewed: Sep. 12, 2022, https://www.nhs.uk/conditions/mesothelioma/, downloaded Jul. 8, 2023, 2 pages.
[cited by applicant]
Bucci et al. “In vivo delivery of the caveolin-1 scaffolding domain inhibits nitric oxide synthesis and reduces inflammation”, Nat. Med. (2000), 6: 1362-1367.
[cited by applicant]
Bussone et al., “Interstitial lung disease in systemic sclerosis”, Autoimmunity Reviews, 10:248-255, 2011.
[cited by applicant]
Campo et al., “A Large Kindred of Pulmonary Fibrosis Associated With a Novel ABCA3 gene variant”, Respiratory Research, 2014, vol. 15, No. 43, p. 1-15.
[cited by applicant]
Carvalho et al., “Influence of particle size on regional lung deposition—What evidence is there?” Int. J Pharma. 406: 1-10, 2011.
[cited by applicant]
CAS RN 246246-98-9. STN Entry Date Dec. 31, 1998, 1 page.
[cited by applicant]
Chang, et al., “Sparc suppresses apoptosis of idiopathic pulmonary fibrosis fibroblasts through constitutive activation of beta-catenin”. J Biol Chem. Mar. 12, 2010; 285(11): 8196-8206. Epub Jan. 8, 2010.
[cited by applicant]
Chen, X. et al. (2013) “Fusion protein linkers: property, design and functionality” Advanced Drug Delivery Reviews, 65(10):1357-1369. (Epub Sep. 29, 2012).
[cited by applicant]
Christiaens, et al., “Tryptophan fluorescence study of the interaction of penetratin peptides with model membranes”. Eur J Biochem. Jun. 2002; 269(12): 2918-2926.
[cited by applicant]
Cohen et al., “Caveolin-1 null mice develop cardiac hypertrophy with hyperactivation of p42/44 MAP kinase in cardiac fibroblasts”, Am J Physiol Cell Physiol., 284:C457-474, 2003.
[cited by applicant]
Cook and Schafer, “Hiding in Plain Sight: Interleukin-11 Emerges as a Master Regulator of Fibrosis, Tissue Integrity, and Stromal Inflammation”. Annu Rev Med. Jan. 27, 2020; 71: 263-276.
[cited by applicant]
Co-pending U.S. Appl. No. 18/547,931, inventors Mackenzie; Breanne et al., filed Aug. 25, 2023.
[cited by applicant]
Costabel, et al., “Hypersensitivity pneumonitis”. Nat Rev Dis Primers. Aug. 6, 2020; 6(1): 65, 19 pages.
[cited by applicant]
Couet et al., “Identification of peptide and protein ligands for the caveolin-scaffolding domain—Implications for the interaction of caveolin with caveolae-associated proteins”, J Biol Chem., 272:6525-6533, 1997.
[cited by applicant]
Couet et al., “Interaction of a receptor tyrosine kinase, EGF-R, with caveolins—Caveolin binding negatively regulates tyrosine and serine/threonine kinase activities”, J Biol Chem., 272:30429-30438, 1997.
[cited by applicant]
Creighton, Protein Biosynthesis, Proteins: Structure and Molecular Properties, W. H. Freeman & Co., San Francisco, pp. 79-86 [1983], 24 pages.
[cited by applicant]
Criado, et al., “Pulmonary sarcoidosis: typical and atypical manifestations at high-resolution CT with pathologic correlation”. Radiographics. Oct. 2010; 30(6): 1567-1586.
[cited by applicant]
Cui et al., “Identification of a specific domain responsible for JNK2alpha2 autophosphorylation”, J Biol. Chem., 280:9913-9920, 2005.
[cited by applicant]
Davis, et al., “Nitric oxide-dependent activation of p53 suppresses bleomycin-induced apoptosis in the lung”. J Exp Med. Sep. 18, 2000; 192(6): 857-869.
[cited by applicant]
Degryse, et al., “Repetitive intratracheal bleomycin models several features of idiopathic pulmonary fibrosis”. Am J Physiol Lung Cell Mol Physiol. Oct. 2010; 299(4): L442-L452. Epub Jun. 18, 2010.
[cited by applicant]
Delatorre et al., “On choosing the right ether for peptide precipitation after acid cleavage,” Journal of Peptide Science, 14(3), 360-363, 2008.
[cited by applicant]
Dempsey, C.E., “The actions of melittin on membranes”. Biochim Biophys Acta. May 7, 1990; 1031(2): 143-161.
[cited by applicant]
Derossi, D., et al., “The third helix of the Antennapedia homeodomain translocates through biological membranes”. J Biol Chem. Apr. 8, 1994 ;269(14): 10444-10450.
[cited by applicant]
Dhand R., “Nebulizers That Use a Vibrating Mesh or Plate With Multiple Apertures to Generate Aerosol”, Respiratory Care, Dec. 2002, vol. 47(12), pp. 1406-1416.
[cited by applicant]
Di Guglielmo, et al., “Distinct endocytic pathways regulate TGF-beta receptor signalling and turnover”. Nat Cell Biol. May 2003; 5(5): 410-421.
[cited by applicant]
Didiasova, et al., “When Place Matters: Shuttling of Enolase-1 Across Cellular Compartments”. Front Cell Dev Biol. Apr. 26, 2019; 7: 61, 11 pages. eCollection 2019.
[cited by applicant]
Dilber, et al., “Intercellular delivery of thymidine kinase prodrug activating enzyme by the herpes simplex virus protein, VP22”. Gene Ther. Jan. 1999; 6(1): 12-21.
[cited by applicant]
Dorange, et al., “Marek's disease virus (MDV) homologues of herpes simplex virus type 1 UL49 (VP22) and UL48 (VP16) genes: high-level expression and characterization of MDV-1 VP22 and VP16”. J Gen Virol. Sep. 2000; 81(P…
[cited by applicant]
Drab et al., “Loss of caveolae, vascular dysfunction, and pulmonary defects in caveolin-1 gene-disrupted mice”, Science, 293:2449-2452, 2001.
[cited by applicant]
Egger, et al., “Administration of bleomycin via the oropharyngeal aspiration route leads to sustained lung fibrosis in mice and rats as quantified by UTE-MRI and histology”. PLoS One. May 7, 2013; 8(5): e63432, 13 pages…
[cited by applicant]
Elliott and O'Hare, “Intercellular trafficking and protein delivery by a herpesvirus structural protein”. Cell. Jan. 24, 1997; 88(2): 223-233.
[cited by applicant]
Epand et al., “Caveolin Scaffolding Region and Cholesterol-rich Domains in Membranes,” Journal of Molecular Biology, 345(2): 339-350, 2005.
[cited by applicant]
Esteve, et al., “Transduction of the scorpion toxin maurocalcine into cells. Evidence that the toxin crosses the plasma membrane”. J Biol Chem. Apr. 1, 2005; 280(13): 12833-12839. Epub Jan. 14, 2005.
[cited by applicant]
Etzerodt et al., “Soluble ectodomain CD163 and extracellular vesicle-associated CD163 are two differently regulated forms of ‘soluble CD163’ in plasma”. Sci Rep. 2017; 7: 40286, 10 pages. Epub Jan. 13, 2017.
[cited by applicant]
Extended European Search Report for European Application No. 14762435.7, dated Nov. 17, 2016, 17 pages.
[cited by applicant]
Extended European Search Report for European Application No. 19859759.3, dated May 17, 2022, 11 pages.
[cited by applicant]
Extended European Search Report for European Application No. 20770567.4, dated Oct. 27, 2022, 10 pages.
[cited by applicant]
Extended European Search Report for European Application No. 21168926.0, dated Nov. 10, 2021, 6 pages.
[cited by applicant]
Extended European Search Report for European Application No. 19859836.9 dated Jun. 3, 2022, 24 pages.
[cited by applicant]
Extended European Search Report for European Application No. 21209064.4, dated Aug. 2, 2022, 13 pages.
[cited by applicant]
Fiddler, et al., “Severe Colitis Associated with Pirfenidone Use in Idiopathic Pulmonary Fibrosis”. Ann Am Thorac Soc. Aug. 2016; 13(8): 1430-1432.
[cited by applicant]
Finch et al., “Bleomycin-induced scleroderma”, J Rheumatol, 7:651-659, 1980.
[cited by applicant]
Frankel and Pabo, “Cellular uptake of the tat protein from human immunodeficiency virus”. Cell. Dec. 23, 1988; 55(6): 1189-1193.
[cited by applicant]
French et al., “What is a Conservative Substitution?,” J Mol. Evol. (1983) 19: 171-175.
[cited by applicant]
Fröhlich and Salar-Behzadi, “Oral inhalation for delivery of proteins and peptides to the lungs”. Eur J Pharm Biopharm. Jun. 2021; 163: 198-211. Epub Apr. 11, 2021.
[cited by applicant]
Fridolfsson, et al., “Regulation of intracellular signaling and function by caveolin”. Faseb J. Sep. 2014; 28(9): 3823-3831. Epub May 22, 2014.
[cited by applicant]
Fults et al., “The influence of sampling chamber dimensions on aerosol particle size measurement by cascade impactor and twin irnpinger,” J. Pharm. Pharmacol. 1991,43: 726-728.
[cited by applicant]
Futaki, S., et al., “Arginine-rich peptides. An abundant source of membrane-permeable peptides having potential as carriers for intracellular protein delivery”. J Biol Chem, 2001. 276(8): p. 5836-5840.
[cited by applicant]
Galbiati et al., “Expression of caveolin-1 and -2 in differentiating PC12 cells and dorsal root ganglion neurons: caveolin-2 is up-regulated in response to cell injury”, Proc Natl Acad Sci USA, 95:10257-10262, 1998.
[cited by applicant]
Gallelli et al., “Severe Acute Lung Injury Related to COVID-19 Infection: A Review and the Possible Role for Escin,” Journal of Clinical Pharmacology, May 2020, vol. 60, pp. 815-825.
[cited by applicant]
Gardenhire et al., “A guide to aerosol delivery devices for respiratory therapists,” American Association for Respiratory Care (2013): 1-56.
[cited by applicant]
Gauldie, et al., “Smad3 Signaling Involved in Pulmonary Fibrosis and Emphysema”. Proc Am Thorac Soc. Nov. 2006; 3(8): 696-702.
[cited by applicant]
Giannis et al., “Peptidomimetics in Drug Design,” Advances in Drug Research, vol. 29, 1997, pp. 1-78.
[cited by applicant]
Gibson, et al., “A novel method for real time quantitative RT-PCR”. Genome Res. Oct. 1996; 6(10): 995-1001.
[cited by applicant]
Gralinski et al., “Mechanisms of severe acute respiratory syndrome corona virus-induced acute lung injury”, mBio, Aug. 2013, vol. 4, e00271-13, pp. 1-12.
[cited by applicant]
Gray et al., “Partially degraded fibrin (ogen) stimulates fibroblast proliferation in vitro”, Am J Resvirator Cell Mol Biol., 12: 684-690, 1995.
[cited by applicant]
Gunther A et al., “Prevention of Bleomycin-induced Lung Fibrosis by Aerosolization of Heparin or Urokinase in Rabbits”, American Journal of Respiratory and Critical Care Medicine, American Lung Association, New York, NY…
[cited by applicant]
Guo et al., “Involvement of caveolin-1 in the Jak-Stat signaling pathway and infectious spleen and kidney necrosis virus infection in mandarin fish (
[cited by applicant]
Gvaramia, et al., “Role of caveolin-1 in fibrotic diseases”. Matrix Biology (2013); 32(6): 307-315.
[cited by applicant]
Hartmann et al., “TIP peptide inhalation in experimental acute lung injury: effect of repetitive dosage and different synthetic variants,” BMC anesthesiology 14 (2014): 42, 8 pages.
[cited by applicant]
Herold et al., “Influenza virus-induced lung injury: pathogenesis and implications for treatment,” European Respiratory Journal, Mar. 2015, vol. 45, pp. 1463-1478.
[cited by applicant]
Hertel et al., “Protein stability in pulmonary drug delivery via nebulization,” Advanced Drug Delivery Reviews 93 (2015) 79-94.
[cited by applicant]
Hiemenz, “Principles of colloid and surface chemistry, 2nd edition” (1986) ISBN 0-8247-7 476-0, 5 pages.
[cited by applicant]
Hocke et al., “Emerging human middle East respiratory syndrome coronavirus causes widespread infection and alveolar damage in human lungs,” American Journal of Respiratory and Critical Care Medicine, Oct. 2013 , vol. 18…
[cited by applicant]
Hong et al., “Differentiation of human circulating fibrocytes as mediated by transforming growth factor-beta and peroxisome proliferators activated receptor-gamma”, J Biol Chem, 2007, 282:22910-22920.
[cited by applicant]
Horton, M. R., et al., “Phase behavior and the partitioning of caveolin-1 scaffolding domain peptides in model lipid bilayers,” J Colloid Interface Sci, Dec. 1, 2006, vol. 304 (1), pp. 67-76.
[cited by applicant]
Hoyle, et al., “Emphysematous lesions, inflammation, and fibrosis in the lungs of transgenic mice overexpressing platelet-derived growth factor”. Am J Pathol. Jun. 1999; 154(6): 1763-1775.
[cited by applicant]
Hruby, “Conformational and Topographical Considerations in the Design of Biologically Active Peptides,” Biopolymers, vol. 33: 1073-1082 (1993).
[cited by applicant]
Hua et al., “Endothelin-1 activates mesangial cell ERK1/2 via EGF-receptor transactivation and caveolin-1 interaction”, Am J Physiol Renal Physiol, 284:F303-312, 2003.
[cited by applicant]
Huang et al., Reduced transcriptional activity in the p53 pathway of senescent cells revealed by the MDM2 antagonist nutlin-3, Aging, 2009, 1(10), 845-54.
[cited by applicant]
Hubner, R.-H et al., “Standardized quantification of pulmonary fibrosis in histological samples,” Biotechniques, 44, 507-11, 514-7, 2008.
[cited by applicant]
International Preliminary Examination Report for International Application No. PCT/US2020/021980, mailed Sep. 23, 2021, 11 pages.
[cited by applicant]
International Preliminary Report on Patentability for International Application No. Application No. PCT/ US2019/050349, mailed on Mar. 25, 2021, 10 pages.
[cited by applicant]
International Preliminary Report on Patentability for International Application No. PCT/US2014/030147, dated Sep. 24, 2015, 9 pages.
[cited by applicant]
International Preliminary Report on Patentability for International Application No. PCT/US2016/019827, dated Aug. 29, 2017, 7pages.
[cited by applicant]
International Preliminary Report on Patentability for International Application No. PCT/US2019/050332, dated Mar. 9, 2021, 7 pages.
[cited by applicant]
International Preliminary Report on Patentability for International Application No. PCT/US2020/021980, dated Aug. 25, 2021, 10 pages.
[cited by applicant]
International Preliminary Report on Patentability for International Application No. PCT/US2021/028326 dated Nov. 3, 2022, 7 pages.
[cited by applicant]
International Preliminary Report on Patentability for International Application No. PCT/US2021/037812, dated Dec. 13, 2022, 9 pages.
[cited by applicant]
International Preliminary Report on Patentability for International Application No. PCT/US2022/017833 dated Sep. 7, 2023, 13 pages.
[cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/US2014/030147, dated Aug. 6, 2014, 16 pages.
[cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/US2016/019827, dated May 25, 2016, 12 pages.
[cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/US2019/050332, dated Dec. 2, 2019, 10 pages.
[cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/US2019/050349, mailed on Dec. 11, 2019, 18 pages.
[cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/US2020/021980, mailed Jun. 24, 2020, 13 pages.
[cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/US2021/028326, mailed on Sep. 9, 2021, 9 pages.
[cited by applicant]
International Search Report and Written Opinion for International Application No. PCTU.S. Pat. No. 2022033929, mailed on Nov. 7, 2022, 17 pages.
[cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/US2022/078482, mailed on Mar. 3, 2023, 11 pages.
[cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/US2022/017833, mailed Aug. 1, 2022.
[cited by applicant]
International Search Report for International Application PCT/US2021/037812 , mailed on Dec. 7, 2021, 14 pages.
[cited by applicant]
Invitation to Pay Fee for International Application No. PCT/US2022/017833 dated May 19, 2022, 4 pages.
[cited by applicant]
Invitation to Pay for International Application No. PCT/US2022/033929 dated Aug. 26, 2022, 2 pages.
[cited by applicant]
Invitation to Pay for International Application No. PCT/US2022/078482 dated Jan. 9, 2023, 2 pages.
[cited by applicant]
Irngartinger, M., et al., “Pulmonary Delivery of Therapeutic Peptides via Dry Powder Inhalation: Effects of Micronisation and Manufacturing,” European Journal of Pharmaceutics and Biopharmaceutics, Jul. 2004, vol. 58(1)…
[cited by applicant]
Ishikawa, et al., “Hemoglobin α and β are ubiquitous in the human lung, decline in idiopathic pulmonary fibrosis but not in COPD”. Respiratory Research 2010; 11, Article No. 123, 13 pages.
[cited by applicant]
Itoga et al., “Factors Affecting Nebulized Albuterol Aerosol Particle Sizes”, Annals of Emergency Medicine, Oct. 1, 2013, vol. 62(4), 2 pages.
[cited by applicant]
Izutsu, Ken-ichi, “Stabilization of therapeutic proteins by chemical and physical methods,” Therapeutic Proteins, Smales and James, eds, ISBN 1-58829-390-4, 2005, Chapter 22, pp. 287-292.
[cited by applicant]
Jin, Y et al., “Caveolin-1: a critical regulator of lung injury”, American Journal of Physiology, Lung Cellular and Molecular Physiology, Feb. 2011, E pub Nov. 19, 2010, vol. 300, No. 2; pp. L151-L157.
[cited by applicant]
Joliot, et al., “Antennapedia homeobox peptide regulates neural morphogenesis”. Proc Natl Acad Sci U S A. Mar. 1, 1991; 88(5): 1864-1868.
[cited by applicant]
Kasper et al., “Loss of caveolin-1 expression in type I pneumocytes as an indicator of subcellular alterations during lung fibrogenesis”, Histochem Cell Biol, 109:41-48, 1998.
[cited by applicant]
Kim et al., “Alveolar epithelial cell mesenchymal transition develops in vivo during pulmonary fibrosis and is regulated by the extracellular matrix”, Proc Natl Acad Sci USA, 103: 13180-13185, 2006.
[cited by applicant]
Kishi, et al., “Blockade of platelet-derived growth factor receptor-β, not receptor-α ameliorates bleomycin-induced pulmonary fibrosis in mice”. PLoS One. Dec. 31, 2018; 13(12): e0209786, 19 pages. eCollection 2018.
[cited by applicant]
Kobayashi, et al., “Membrane translocation mechanism of the antimicrobial peptide buforin 2”. Biochemistry. Dec. 14, 2004; 43(49): 15610-15616.
[cited by applicant]
Konishi, et al., “Gene expression profiles of acute exacerbations of idiopathic pulmonary fibrosis”. Am J Respir Crit Care Med. Jul. 15, 2009; 180(2): 167-175. Epub Apr. 10, 2009.
[cited by applicant]
Konno, et al., “Structure and biological activities of eumenine mastoparan-AF (EMP-AF), a new mast cell degranulating peptide in the venom of the solitary wasp (Anterhynchium flavomarginatum micado)”. Toxicon. Nov. 2000…
[cited by applicant]
Koptidesova, et al., “Identification and characterization of a cDNA clone derived from the Marek's disease tumour cell line RPL1 encoding a homologue of alpha-transinducing factor (VP16) of HSV-1”. Arch Virol. 1995; 140…
[cited by applicant]
Korfei, et al., “The ageing lung under stress,” Eur Respir Rev, Jun. 2020, vol. 29(156), 200126, 22 pages.
[cited by applicant]
Korf-Klingebiel, et al., “Myeloid-derived growth factor (C19orf10) mediates cardiac repair following myocardial infarction”. Nat Med. Feb. 2015; 21(2): 140-149. Epub Jan. 12, 2015.
[cited by applicant]
Kummer, et al., “Vascular Signaling in Allogenic Solid Organ Transplantation—The Role of Endothelial Cells.” Front Physiol. May 8, 2020; 11: 443, 19 pages. eCollection 2020.
[cited by applicant]
Kunz, “Synthesis of Glycopeptides, Partial Structures of Biological Recognition Components [New Synthetic Methods (67)]†‡”. Angewandte Chemie International Ed., vol. 26, Issue 4, Apr. 1987, pp. 294-308.
[cited by applicant]
Kyte, J. and R.F. Doolittle (May 5, 1982) “A simple method for displaying the hydropathic character of a protein” J Mol Biol, 157(1):105-132.
[cited by applicant]
Lee, et al., “Expression of Caveolin-1 reduces cellular responses to TGF-beta1 through down-regulating the expression of TGF-beta type II receptor gene in NIH3T3 fibroblast cells”. Biochem Biophys Res Commun. Jul. 27, 2…
[cited by applicant]
Lesaux et al., “Down-regulation of caveolin-1, an inhibitor of transforming growth factor-β signaling, an acute allergen-induced airway remodeling”, The Journal of Biological Chemistry, 283(9): 5760-5768, 2008.
[cited by applicant]
Levin et al., “Double barrel shotgun scanning of the caveolin-1 scaffolding domain”, ACS Chemical Biology, 2(7): 493-500, 2007.
[cited by applicant]
Li, et al., “Effect of platelet-derived growth factor on the development and persistence of asbestos-induced fibroproliferative lung disease”. J Environ Pathol Toxicol Oncol. 2004; 23(4): 253-266.
[cited by applicant]
Lindgren, et al., “Cell-penetrating peptides”. Trends Pharmacol Sci. Mar. 2000; 21(3): 99-103.
[cited by applicant]
Lindgren, et al., “Translocation properties of novel cell penetrating transportan and penetratin analogues”. Bioconjug Chem. Sep.-Oct. 2000; 11(5): 619-626.
[cited by applicant]
Lisanti et al., “Characterization of caveolin-rich membrane domains isolated from an endothelial-rich source: implications for human disease”, J Biol Chem, 126: 111-126, 1994.
[cited by applicant]
Liu, et al., “Fibroblast-specific expression of AC6 enhances beta-adrenergic and prostacyclin signaling and blunts bleomycin-induced pulmonary fibrosis”. Am J Physiol Lung Cell Mol Physiol. Jun. 2010; 298(6): L819-L829.
[cited by applicant]
Liu, et al., “p53 Attenuates lipopolysaccharide-induced NF-kappaB activation and acute lung injury”. J Immunol. Apr. 15, 2009; 182(8): 5063-5071.
[cited by applicant]
Mace, et a., “HOXA3 induces cell migration in endothelial and epithelial cells promoting angiogenesis and wound repair”. J Cell Sci. Jun. 15, 2005; 118(Pt 12): 2567-2577. Epub May 24, 2005.
[cited by applicant]
Mackenzie, et al., U.S. Appl. No. 18/002,420, filed Dec. 19, 2022 for Modified Caveolin-1 Peptides for the Treatment of Pathogen-Induced Lung Injury.
[cited by applicant]
Malinmvsky, et al., “uPA and PAI-1-Related Signaling Pathways Differ between Primary Breast Cancers and Lymph Node Metastases”. Transl Oncol. Apr. 2012; 5(2): 98-104. Epub Apr. 1, 2012.
[cited by applicant]
Manichaikul, et al., “Plasma Soluble Receptor for Advanced Glycation End Products in Idiopathic Pulmonary Fibrosis”. Ann Am Thorac Soc. May 2017; 14(5): 628-635.
[cited by applicant]
Maniti, et al., “Distinct behaviour of the homeodomain derived cell penetrating peptide penetratin in interaction with different phospholipids”. PLoS One. Dec. 30, 2010; 5(12): e15819, 11 pages.
[cited by applicant]
Markarian, Jennifer, “optimizing Particle Engineering Methods for Inhalation Drug Products”, Inhalation Drug Manufacturing, Pharmaceutical Technology (2018); 42(4): 34-46.
[cited by applicant]
Marudamuthu, A.S., et al., “Caveolin-1-Derived Peptide Limits Development of Pulmonary Fibrosis,” Science translational medicine, Dec. 11, 2019, vol. 11(522), 16 pages.
[cited by applicant]
Marudamuthu, et al., “Role of the urokinase-fibrinolytic system in epithelial-mesenchymal transition during lung injury”. Am J Pathol. Jan. 2015; 185(1): 55-68. Epub Nov. 3, 2014.
[cited by applicant]
Matthay et al., “The acute respiratory distress syndrome,” The Journal of Clinical Investigation, vol. 122, No. 8, Aug. 2012, pp. 2731-2740.
[cited by applicant]
Mayo LD, et al., “PTEN protects p53 from Mdm2 and sensitizes cancer cells to chemotherapy”. J Biol Chem. Feb. 15, 2002; 277(7): 5484-5489. Epub Nov. 29, 2001.
[cited by applicant]
Mclean et al., “Optical Patternation: A Technique for Three-Dimensional Aerosol Diagnostics,” Analytical Chemistry, vol. 72, No. 20, Oct. 15, 2000, pp. 4796-4804.
[cited by applicant]
Meinecke, et al., “Aberrant mural cell recruitment to lymphatic vessels and impaired lymphatic drainage in a murine model of pulmonary fibrosis”. Blood. Jun. 14, 2012; 119(24): 5931-5942. Epub Apr. 30, 2012.
[cited by applicant]
Merkel, et al., “Interdependent regulation of p53 and miR-34a in chronic lymphocytic leukemia”. Cell Cycle. Jul. 15, 2010; 9(14): 2764-2768. Epub Jul. 3, 2010.
[cited by applicant]
Meyer et al., An international ISHLT/ATS/ERS clinical practice guideline: diagnosis and management of bronchiolitis obliterans syndrome, Eur. Respir. J., Oct. 30, 2014: 44: pp. 1479-1503.
[cited by applicant]
Michel, et al., “Caveolin versus calmodulin.” J Biol Chem. Oct. 10, 1997; 272(41): 25907-25912.
[cited by applicant]
Milletti, “Cell-penetrating peptides: classes, origin, and current landscape”. Drug Discov Today. Aug. 2012; 17(15-16): 850-860. Epub Mar. 23, 2012.
[cited by applicant]
Mimura et al., “Constitutive phosphorylation of focal adhesion kinase is involved in the myofibroblast differentiation of scleroderma fibroblasts”, J Invest Dermatol, 124: 886-892, 2005.
[cited by applicant]
Mitchell et al., A New Synthetic Route to tert-Butyloxycarbonylaminoacyl-4-(oxymethyl) phenylacetamidomethyl-resin, an Improved Support for Solid-Phase Peptide Synthesis, J. Org. Chem., vol. 43, No. 14, 1978, pp. 2845-2…
[cited by applicant]
Miyasato, et al., “Caveolin-1 modulates TGF-β1 signaling in cardiac remodeling.” Matrix Biol. Jun. 2011; 30(5-6): 318-329. Epub May 27, 2011.
[cited by applicant]
Münster, Anna-Marie, et al., “Jet and ultrasonic nebulization of single chain urokinase plasminogen activator (scu-PA).” J Aerosol Med. 2000 Winter; 13(4): 325-333.
[cited by applicant]
Moore et al., “CCR2-mediated recruitment of fibrocytes to the alveolar space after fibrotic injury”, Am J Pathol, 166: 675-684, 2005.
[cited by applicant]
Moore et al., “Design and Pharmacology of Peptide Mimetics,” Advances in Pharmacology, vol. 33, pp. 91-141 (1995).
[cited by applicant]
Morris et al., “A peptide carrier for the delivery of biologically active proteins into mammalian cells”. Nat Biotechnol. Dec. 2001; 19(12): 1173-1176.
[cited by applicant]
Muller et al., “Redistribution of glycolipid raft domain components induces insulinmimetic signaling in rat adipocytes”, Mol Cell Biol., 21:4553-4567, 2001.
[cited by applicant]
Myers et al., “The science guiding selection of an aerosol delivery device”, Respiratory care, Nov. 1, 2013, vol. 58(11), pp. 1963-1973.
[cited by applicant]
Nagaraja et al., “p53 Expression in Lung Fibroblasts Is Linked to Mitigation of Fibrotic Lung Remodeling,” The American Journal of Pathology, Oct. 2018, vol. 188(10), pp. 2207-2222.
[cited by applicant]
Nalbandian A., et al., “Post-acute COVID-19 syndrome” Nature Medicine, Mar. 22, 2021, vol. 27, pp. 601-615.
[cited by applicant]
Nascimento, et al., “Crotamine mediates gene delivery into cells through the binding to heparan sulfate proteoglycans”. J Biol Chem. 2007; 282(29): 21349-21360.
[cited by applicant]
Odajima et al., “Loss of caveolin-1 in bronchiolization in lung fibrosis”, Journal of Histochemistry & Cytochemistry, 55(9): 899-909, 2007.
[cited by applicant]
Oka et al., “Caveolin interaction with protein kinase C”, J Biol Chem, 272:33416-33421, 1997.
[cited by applicant]
Okamoto et al., “Caveolins, a family of scaffolding proteins for organizing ‘pre-assembled signaling complexes’ at the plasma membrane”, J Biol Chem, 273:5419-5422, 1998.
[cited by applicant]
Oparah, et al., “Operative management of penetrating wounds of the chest in civilian practice.” J Thorac Cardiovasc Surg. Feb. 1979; 77(2): 162-168.
[cited by applicant]
Osier et al., “Intratracheal Inhalation vs Intratracheal Instillation: Differences in Particle Effects,” Fundam. Appl. Toxicol., 40:220-227, 1997.
[cited by applicant]
Padro, et al., “The catalytic domain of endogenous urokinase-type plasminogen activator is required for the mitogenic activity of platelet-derived and basic fibroblast growth factors in human vascular smooth muscle cell…
[cited by applicant]
Palmer, Brian; “The science of sea spray”, dated May 21, 2015, downloaded fromhttps://www.nrdc.org/onearth/science-sea-spray, on Oct. 25, 2018, 7 pages.
[cited by applicant]
Pannu et al., “Transforming Growth Factor-beta receptor type I-dependent fibrogenic gene program is mediated via activation of Smad1 and ERK1/2 pathways”, J Biol Chem, 282: 10405-10413, 2007.
[cited by applicant]
Phelan, et al., “Intercellular delivery of functional p53 by the herpesvirus protein VP22”. Nat Biotechnol. May 1998; 16(5): 440-443.
[cited by applicant]
Phillips et al., “Circulating fibrocytes traffic to the lungs in response to CXCL 12 and mediate fibrosis”, J Clin Invest, 114: 438-446, 2004.
[cited by applicant]
Pooga, et al., “Cell penetration by transportan”. Faseb J. Jan. 1998; 12(1): 67-77.
[cited by applicant]
Quan et al., “The role of the circulating fibrocytes in fibrosis”, Curr Rheumatol Rep, 8: 145-150, 2006.
[cited by applicant]
Quanlin Li, “New medicine development and research”, China Medical Science Press, published on Dec. 31, 2008; pp. 668-669, paragraph 4, pp. 674, pp. 675-676.
[cited by applicant]
Rabe et al., “Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease,” Am. J. Respir. Crit. Care Med., vol. 176, May 16, 2007, pp. 532-555.
[cited by applicant]
Rafii, R., et al., “A review of current and novel therapies for idiopathic pulmonary fibrosis”. J Thorac Dis. Feb. 2013; 5(1): 48-73.
[cited by applicant]
Ralston et al., “Clinical Practice Guideline: The Diagnosis, Management, and Prevention of Bronchiolitis,” Pediatrics, vol. 134, No. 5, Nov. 2014, 31 pages.
[cited by applicant]
Razani et al., “Caveolae: from cell biology to animal physiology”, Pharmacol Rev, 54:431-467, 2002.
[cited by applicant]
Razani et al., “Caveolin-1 null mice are viable but show evidence of hyperproliferative and vascular abnormalities”, J Biol Chem., 276:38121-38138, 2001.
[cited by applicant]
Razani, et al., “Caveolin-1 Regulates Transforming Growth Factor (TGF)-b/SMAD Signaling through an Interaction with the TGF-ß Type I Receptor”. J Biol Chem. Mar. 2, 2001; 276(9): 6727-3738. Epub Dec. 1, 2000.
[cited by applicant]
Razani et al., “Regulation of cAMP-mediated signal transduction via interaction of caveolins with the catalytic subunit of protein kinase A”, J Biol Chem., 274:26353-26360, 1999.
[cited by applicant]
Respaud et al., “Effect of formulation on the stability and aerosol performance of a nebulized antibody.” MAbs. (2014); vol. 6. No. 5. 1347-1355.
[cited by applicant]
“Retsch technology sales literature for light scatterers”, downloaded from https://www.retsch-technology.com/products/laser-light-scattering/, on Jun. 11, 2019, 5 pages.
[cited by applicant]
Rybin et al., “Activated protein kinase C isoforms target to cardiomyocyte caveolae: stimulation of local protein phosphorylation”, Circ Res, 84: 980-988, 1999.
[cited by applicant]
Sanders, et al., “Epigenetic Regulation of Caveolin-1 Gene Expression in Lung Fibroblasts”. Am J Respir Cell Mol Biol. Jan. 2017; 56(1): 50-61.
[cited by applicant]
Sanders, et al., “SMAD-independent down-regulation of caveolin-1 by TGF-β: effects on proliferation and survival of myofibroblasts”. PLoS One. Feb. 6, 2015; 10(2): e0116995, 18 pages. eCollection 2015.
[cited by applicant]
Schellenberger et al., “A recombinant polypeptide extends the in vivo half-life of peptides and proteins in a tunable manner,” Nature Biotechnology, vol. 27, No. 12, Dec. 2009, 7 pages.
[cited by applicant]
Scherer et al., “Caveolin isoforms differ in their N-terminal protein sequence and subcellular distribution. Identification and epitope mapping of an isoform-specific monoclonal antibody probe”, J Biol Chem., 270: 16395…
[cited by applicant]
Schmitz, M., et al., “Effect of Cavtratin, a Caveolin-1 Scaffolding Domain Peptide, on Oligodendroglial Signaling Cascades,” Cellular and Molecular Neurobiology, Oct. 2011, vol. 31 (7), pp. 991-997, XP019955941.
[cited by applicant]
Sedding et al., “Caveolin-1 facilitates mechanosensitive protein kinase B (Akt) signaling in vitro and in vivo”, Circ Res, 96: 635-642, 2005.
[cited by applicant]
Sharma et al., “Bleomycin-induced scleroderma”, JAPI, 52:76-77, 2004.
[cited by applicant]
Shaul et al., “Role of plasmalemmal caveolae in signal transduction”, AJP Lung Cell Mol Phys, 275:L843-L851, 1998.
[cited by applicant]
Shetty, et al., “A urokinase receptor mRNA binding protein from rabbit lung fibroblasts and mesothelial cells”. Am J Physiol. Jun. 1998; 274(6): L871-L882.
[cited by applicant]
Shetty, et al., “Differential expression of the urokinase receptor in fibroblasts from normal and fibrotic human lungs”. Am J Respir Cell Mol Biol. Jul. 1996; 15(1): 78-87.
[cited by applicant]
Shetty et al., “Induction of p53 by Urokinase in Lung Epithelial Cells,” The Journal of Biological Chemistry, vol. 280, No. 30, Issue of Jul. 29, pp. 28133-28141, 2005.
[cited by applicant]
Shetty et al., “Physical stability of dry powder inhaler formulations,” Expert Opin Drug Deliv. Jan. 2020; 17(1): 77-96.
[cited by applicant]
Shetty, et al., “Regulation of mesothelial cell mitogenesis by antisense oligonucleotides for the urokinase”. Antisense Res Dev. 1995 Winter; 5(4): 307-314.
[cited by applicant]
Shetty, et al., “Regulation of plasminogen activator inhibitor-1 expression by tumor suppressor protein p53”. J Biol Chem. Jul. 11, 2008; 283(28): 19570-19580. Epub May 9, 2008.
[cited by applicant]
Shetty, et al., “Regulation of urokinase receptor expression by p53: novel role in stabilization of uPAR mRNA”. Mol Cell Biol. Aug. 2007; 27(16): 5607-5618. Epub Jun. 4, 2007.
[cited by applicant]
Shetty, et al., “Urokinase expression by tumor suppressor protein p53: a novel role in mRNA turnover”. Am J Respir Cell Mol Biol. Sep. 2008; 39(3): 364-372. Epub Apr. 3, 2008.
[cited by applicant]
Shetty, et al., “Urokinase induces expression of its own receptor in Beas2B lung epithelial cells”. J Biol Chem. Jul. 6, 2001; 276(27): 24549-24556. Epub May 7, 2001.
[cited by applicant]
Shetty, et al., “Urokinase receptor in human malignant mesothelioma cells: role in tumor cell mitogenesis and proteolysis”. Am J Physiol. Jun. 1995; 268(6 Pt 1): L972-L982.
[cited by applicant]
Shetty, et al., “Urokinase receptor mRNA stability involves tyrosine phosphorylation in lung epithelial cells”. Am J Respir Cell Mol Biol. Jan. 2004; 30(1): 69-75. Epub Jun. 19, 2003.
[cited by applicant]
Shetty, et al., U.S. Appl. No. 18/061,084, filed Dec. 2, 2022 for Inhibition of Pulmonary Fibrosis With Nutlin-3A and Peptides.
[cited by applicant]
Shetty, S. K., et al., “Regulation of airway and alveolar epithelial cell apoptosis by p53-Induced plasminogen activator inhibitor-1 during cigarette smoke exposure injury,” Am J Respir Cell Mol Biol, Oct. 2012, vol. 47…
[cited by applicant]
Shitata, et al., “Is There a Potential Therapeutic Role for Caveolin-1 in Fibrosis?” Front. Pharmacol. 2017; 8(1): 567, 8 pages.
[cited by applicant]
Shi-Wen et al., “Constitutive ALK5-independent c-Jun N-Terminal Kinase activation contributes to endothelin-1 overexpression in pulmonary fibrosis: evidence of an autocrine endothelin loop operating through the endothel…
[cited by applicant]
Shi-Wen et al., “Endothelin-1 promotes myofibroblast induction through the ETA receptor via a rac/Phosphoinositide 3-kinase/Akt-dependent pathway and is essential for the enhanced contractile phenotype of fibrotic fibro…
[cited by applicant]
Silver, “Interstitial lung disease of systemic sclerosis”, Int Rev Immunol., 12:281-291, 1995.
[cited by applicant]
Singh et al., “Transdermal Drug Delivery by Passive Diffusion and Iontophoresis: A Review,” Medicinal Research Reviews, vol. 13, No. 5, 569-621 (1993).
[cited by applicant]
Solomon et al., “Scleroderma lung disease”. Eur Respir Rev. Mar. 1, 2013; 22(127): 6-19.
[cited by applicant]
Song et al., “Co-precipitation and direct interaction of Ras with caveolin, an integral membrane protein of caveolae microdomains”, J Biol Chem, 271 :9690-9697, 1996.
[cited by applicant]